Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Completed · Phase 1

Conditions studied: Pain

In brief

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of VX-548 and its metabolite in participants with severe or moderate renal impairment and healthy participants.

Key facts

Study ID

NCT05704556

Run by

Vertex Pharmaceuticals Incorporated

People needed

38

Starts

2023-02-27

Expected to finish

2024-03-30

Last updated by the study team

2024-04-29

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

• Infigo Clinical Research — DeLand, Florida, United States
• Clinical Pharmacology of Miami, LLC — Miami, Florida, United States
• GCP Research — St. Petersburg, Florida, United States
• Genesis Clinical Research — Tampa, Florida, United States
• Elixia, Phase 1 Clinical Site — Tampa, Florida, United States
• Southwest Houston Research, Ltd — Houston, Texas, United States
• Clinical Trials of Texas, LLC — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.